{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:51:41Z","timestamp":1778626301795,"version":"3.51.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.det.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:51:02Z","timestamp":1737463862000},"page":"203-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Challenges of Assessing Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"43","author":[{"given":"Neha","family":"Iska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham T.","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaveont\u00e9","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ndidi","family":"Enwereji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Daveluy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.det.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","article-title":"Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice: a HiSTORIC consensus statement","volume":"159","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project","volume":"82","author":"Garg","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project","volume":"187","author":"Midgette","year":"2022","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","article-title":"Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice: a HiSTORIC consensus statement","volume":"159","author":"Mastacouris","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib5","doi-asserted-by":"crossref","DOI":"10.2196\/27869","article-title":"Trends in hidradenitis suppurativa disease severity and quality of life outcome measures: scoping review","volume":"4","author":"Maghfour","year":"2021","journal-title":"JMIR Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice: hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.det.2015.07.002","article-title":"The genetics of hidradenitis suppurativa","volume":"34","author":"Ingram","year":"2016","journal-title":"Dermatol Clin"},{"issue":"10","key":"10.1016\/j.det.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/jid.2012.162","article-title":"Mutations in the \u03b3-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa)","volume":"132","author":"Pink","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/cjp.cjp_67_21","article-title":"Hidradenitis suppurativa: disease pathophysiology and sex hormones","volume":"64","author":"Chu","year":"2021","journal-title":"Chin J Physiol"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/00015555-2513","article-title":"Hurley staging refined: a proposal by the Dutch hidradenitis suppurativa expert group","volume":"97","author":"Horv\u00e1th","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis","volume":"71","author":"Shlyankevich","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40257-016-0220-6","article-title":"Adalimumab: a review in hidradenitis suppurativa","volume":"17","author":"Kim","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamadermatol.2018.2117","article-title":"Association of low socioeconomic status with hidradenitis suppurativa in the United States","volume":"154","author":"Wertenteil","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jaad.2016.04.067","article-title":"Hidradenitis suppurativa(HS) is associated with low socioeconomic status (SES): a cross-sectional reference study","volume":"75","author":"Deckers","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib17","series-title":"Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: results from pioneer ii, a phase 3, randomized, placebo-controlled trial. abstract FC08.2","author":"Jemec","year":"2014"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib19","series-title":"Dermatologic surgery","first-page":"729","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1989"},{"key":"10.1016\/j.det.2024.12.006_bib20","first-page":"e248","article-title":"A\u00a0survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa","volume":"60","author":"Shaver","year":"2020","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjd.17588","article-title":"Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa","volume":"181","author":"vadja","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.006_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib24","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/bjd.14038","article-title":"Diagnostic delay in hidradenitis suppurativa is a global problem","volume":"173","author":"Saunte","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib25","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.20078","article-title":"Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study","volume":"185","author":"Prens","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment","volume":"180","author":"Rondags","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/09546634.2017.1395806","article-title":"Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing\u2216 clinical trials","volume":"29","author":"Maarouf","year":"2018","journal-title":"J\u00a0Dermatol Treat"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000501771","article-title":"Could residents adequately assess the severity of hidradenitis suppurativa? interrater and intrarater reliability assessment of major scoring systems","volume":"236","author":"W\u0142odarek","year":"2020","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjd.21236","article-title":"Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials","volume":"187","author":"Garg","year":"2022","journal-title":"Br J Dermatol"},{"issue":"Issue Supplement_4","key":"10.1016\/j.det.2024.12.006_bib32","article-title":"P90 Adalimumab treatment for hidradenitis suppurativa: a retrospective analysis of demographics, patient characteristics and treatment outcomes for 107 patients from a tertiary dermatology centre","volume":"188","author":"O\u2019Connor","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ced.14889","article-title":"Assessment of inter-rater reliability of clinical hidradenitis suppurativa outcome measures using ultrasonography","volume":"47","author":"Lyons","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib34","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.det.2024.12.006_bib36","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/jdv.15163","article-title":"Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa","volume":"32","author":"Kimball","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.12.006_bib37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.det.2024.12.006_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/exd.14609","article-title":"New treatments and new assessment instruments for Hidradenitis suppurativa","volume":"31","author":"van Straalen","year":"2022","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib39","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib40","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1016\/j.jval.2023.03.2776","article-title":"PCR234 impact of draining tunnels on patient- and physician-reported burden in patients with hidradenitis suppurativa (HS)","volume":"26","author":"Kirby","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.det.2024.12.006_bib41","first-page":"e496","article-title":"International hidradenitis suppurativa severity scoring system (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: a post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab","volume":"38","author":"Zouboulis","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/bjd\/ljae098","article-title":"Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials","volume":"190","author":"Zouboulis","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000535867","article-title":"Viewpoint on the evaluation of severity and treatment effects in mild hidradenitis suppurativa: the cumulative IHS4","volume":"240","author":"van der Zee","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib47","article-title":"Automatic International Hidradenitis Suppurativa Severity Score System (AIHS4): a novel tool to assess the severity of hidradenitis suppurativa using artificial intelligence","volume":"29","author":"Montilla","year":"2023","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.det.2024.12.006_bib48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjd.18244","article-title":"Severity and area score for hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamadermatol.2023.0797","article-title":"Validation of the Hidradenitis Suppurativa Investigator Global Assessment: a novel hidradenitis suppurativa\u2013 specific investigator global assessment for use in interventional trials","volume":"159","author":"Garg","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2023.0784","article-title":"The critical need for reliable and clinically meaningful outcome measures for hidradenitis suppurativa","volume":"159","author":"Naik","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"15","key":"10.1016\/j.det.2024.12.006_bib51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.2014.11100","article-title":"The PCORI perspective on patient-centered outcomes research","volume":"312","author":"Frank","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.det.2024.12.006_bib52","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s11136-011-0054-x","article-title":"Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations","volume":"21","author":"Snyder","year":"2012","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.det.2011.11.010","article-title":"Clinical meaning in skin-specific quality of life instruments: a comparison of the Dermatology life quality index and skindex banding systems","volume":"30","author":"Rogers","year":"2012","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib55","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A\u00a0core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2017.1341614","article-title":"Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa","volume":"29","author":"Kimball","year":"2018","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1203475416677721","article-title":"Development of a quality-of-life measure for hidradenitis suppurativa","volume":"21","author":"Sisic","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000496234","article-title":"Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument","volume":"5","author":"Thorlacius","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.det.2024.12.006_bib59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.19344","article-title":"Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa","volume":"184","author":"Kirby","year":"2021","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.006_bib61","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-4632.2010.04545.x","article-title":"A\u00a0prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa","volume":"49","author":"Amano","year":"2010","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.12.006_bib62","first-page":"258","article-title":"AISI: a new disease severity assessment tool for hidradenitis suppurativa","volume":"27","author":"Chiricozzi","year":"2015","journal-title":"Wounds"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib63","first-page":"240","article-title":"Hidradenitis suppurativa area and severity index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa","volume":"182","author":"Goldfarb","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib64","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjd.19565","article-title":"Hidradenitis suppurativa area and severity index revised (HASI-R): psychometric property assessment","volume":"184","author":"Goldfarb","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/bjd\/ljad138","article-title":"Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity","volume":"189","author":"Bellefeuille","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib66","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bjd\/ljae144","article-title":"Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial","volume":"191","author":"Alavi","year":"2024","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.12.006_bib67","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jdv.16328","article-title":"Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore","volume":"34","author":"Marzano","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2024.12.006_bib68","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","article-title":"A\u00a0novel severity assessment scoring system for hidradenitis suppurativa","volume":"154","author":"Hessam","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10488-006-0110-y","article-title":"Why some clinicians use outcome measures and others do not","volume":"34","author":"Hatfield","year":"2007","journal-title":"Admin Policy Ment Health"},{"issue":"17","key":"10.1016\/j.det.2024.12.006_bib70","article-title":"Overview and comparison of the clinical scores in Hidradenitis Suppurativa: a real-life clinical data","volume":"10","author":"Daoud","year":"2023","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.det.2024.12.006_bib71","article-title":"Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review","volume":"10","author":"Snyder","year":"2024","journal-title":"Int J Womens Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaad.2019.05.065","article-title":"Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review","volume":"82","author":"Amir Ali","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.006_bib73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.det.2024.12.006_bib74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11916-014-0419-2","article-title":"Understanding placebo and nocebo responses for pain management","volume":"18","author":"Colloca","year":"2014","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.det.2024.12.006_bib75","doi-asserted-by":"crossref","first-page":"xv","DOI":"10.1016\/S0074-7742(18)30027-8","article-title":"Preface: the fascinating mechanisms and\u00a0implications of the placebo effect","volume":"138","author":"Colloca","year":"2018","journal-title":"Int Rev Neurobiol"},{"issue":"11","key":"10.1016\/j.det.2024.12.006_bib76","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib77","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1111\/jdv.17022","article-title":"Metascoring hidradenitis suppurativa","volume":"35","author":"Daoud","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.12.006_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.det.2015.08.003","article-title":"Imaging of hidradenitis suppurativa","volume":"34","author":"Wortsman","year":"2016","journal-title":"Dermatol Clin"},{"issue":"S6","key":"10.1016\/j.det.2024.12.006_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jdv.15847","article-title":"Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience","volume":"33","author":"Lacarrubba","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2024.12.006_bib80","first-page":"e413","article-title":"Ultrasound: an indispensable tool to evaluate the outcome of surgical approaches in patients affected by hidradenitis suppurativa","volume":"34","author":"Marasca","year":"2020","journal-title":"J\u00a0Eur Acad Dermatology Vener- eol"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/srt.12823","article-title":"Advanced evaluation of hidradenitis suppurativa with ultra-high frequency ultrasound: a promising tool for the diagnosis and monitoring of disease progres- sion","volume":"26","author":"Oranges","year":"2020","journal-title":"Skin Res Technol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib82","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jum.15164","article-title":"Seventy mhz ultrasound detection of early signs linked to the severity, patterns of keratin fragmentation, and mechanisms of generation of collections and tunnels in hidradenitis suppurativa","volume":"39","author":"Wortsman","year":"2020","journal-title":"J\u00a0Ultrasound Med"},{"key":"10.1016\/j.det.2024.12.006_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.15710","article-title":"Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study","author":"Martorell","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.12.006_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16435","article-title":"Pre-operative ultrasound planning in the surgical management of patients with hidradenitis suppurativa","author":"Cuenca-Barrales","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.det.2024.12.006_bib85","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/dsu.12329","article-title":"Ultrasound in-depth characterization and staging of hidradenitis suppurativa","volume":"39","author":"Wortsman","year":"2013","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.det.2024.12.006_bib86","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.05.009","article-title":"Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS)","volume":"75","author":"Wortsman","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.006_bib87","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2214\/AJR.04.1233","article-title":"MRI features of hidradenitis suppurativa and review of the literature","volume":"185","author":"Kelly","year":"2005","journal-title":"Am J Roentgenol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:30:40Z","timestamp":1751391040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0733863524001062"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.12.006","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Challenges of Assessing Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}